Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.74 |
| ▸ | NADK | O95544 | 1/20 | 0.74 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.74 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.74 |
| ▸ | PNMT | P11086 | 2/20 | 0.74 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.74 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.68 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.68 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.68 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.68 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.68 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.68 |
| ▸ | INMT | O95050 | 1/20 | 0.68 |
| ▸ | NSD2 | O96028 | 1/20 | 0.68 |
| ▸ | NNMT | P40261 | 1/20 | 0.68 |
| ▸ | HNMT | P50135 | 1/20 | 0.68 |
| ▸ | WDR5 | P61964 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116141 | 1.00 | AHCY (0.74) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL29382766 | 1.00 | AHCY (0.74) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL2115821 | 0.88 | AHCY (0.79) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL998091 | 0.88 | AHCY (0.79) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL6935387 | 0.87 | AHCY (0.78) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL21243035 | 0.87 | DOT1L (0.84) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL19433069 | 0.87 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL95173 | 0.87 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL18661551 | 0.87 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT | |
| SCHEMBL27092961 | 0.87 | DOT1L (0.82) | AHCYNADKDOT1LDNMT3BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| JP-5208993-A | — | — | None | — | — | JP | disclosed |
| US-20200087630-A1 | INFLUENZA VIRUS AND TYPE 1 DIABETES | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-03-19 | — | — | US | disclosed |
| US-20180273912-A1 | INFLUENZA VIRUS AND TYPE 1 DIABETES | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2018-09-27 | — | — | US | disclosed |
| US-20150299667-A1 | INFLUENZA VIRUS AND TYPE 1 DIABETES | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2015-10-22 | — | — | US | disclosed |
| EP-2906231-A2 | INFLUENZA VIRUS AND TYPE 1 DIABETES | Ospedale San Raffaele S.r.l. (IT) | 2015-08-19 | — | — | EP | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100047273-A1 | Coxsackie B virus and type 1 diabetes | RAPPUOLI RINO | 2010-02-25 | — | — | US | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| JP-H05208993-A | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ISCHEMIA | BIORESEARCH SPA | 1993-08-20 | — | — | JP | disclosed |
| EP-0233031-B1 | METHYLTHIORIBOSE ANALOGUES, THEIR PREPARATION AND USE AS MEDICINAL AGENTS AND BIOCIDES | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1993-04-07 | — | — | EP | disclosed |
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | disclosed |
| US-4948783-A | ORALLY ADMINISTERING ADENOSINE OR DERIVATIVE | KABUSHIKI KAISYA ADVANCE KAIHATSU KENKYUJO (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047273-A1 | Coxsackie B virus and type 1 diabetes | IAPP, IRS1, RNASE1 | AHCY 4642/4885NADK 2738/4885DOT1L 4434/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | AHCY 62/4885NADK 1514/4885DOT1L 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.